Member Info for clairesmith

thats a really good day over at ITX, will add that to the watch list :)

painful to watch the price sink on what essentially is a good layout of the amazing products and work happening over.

might put a high sell out price on and put in the forget and move on category

well the outlay of the new RNS is a great roadmap of 2021 and the massive potential of this company

if the GAD patent comes in place, considering the fear of literation in the USA , I can quickly seeing this becoming the standard.

Combined with the reduced costs to the hospitals in buying and handling chemicals.

this further drives the usage and need of all of IQAI product ranges. very smart move.

looks like by the end of 2021 they will have a very wide and diverse portfolio of AI medical tech, with lots of revenue streams.
and cancer checking being one of the most lucrative areas to get involved in.
so this is a win win, the patients getting access to great tech that can save lives, and IQAI being in a massive continuous revenue stream.

basically they are working with the 3 biggest medical tech companies.

if you wanted 3 friends to make sure your products are being pushed into every hospital globally these are the guys to be working with.

Basically the company moving into 2021 has and insane amount of different product updates, roll outs, and new developments happening. And a diverse portfolio to have multiple streams of revenue.
Combined with partnerships with the leading medical companies in one of the fastest growing medical tech area.
And their marketing and sales are working fully to ensure mass roll out and adoption.

2021 = massive year for IQAI

would be better if we got to clear out a few more holders from the 4 region. so over the next few days a strong tree shake would benefit more longer term holders.

However i expect massive things for graphene this year, and Haydale are a big part of this.

It's amazing news

Between Bayer and the Arterys AI medical platform IQAI are getting massive reach to massive audience, and crucial a key vendor on these platforms.

2021 is turning into the year that medical AI can take off and become a important part of modern medicine

was in the process of arranging funds to do a buy tomorrow, and looks like i missed the train today, however the price is still so low that happy to put in still as this has massive growth potential

tightly held, I think most holders can see the massive potential, and when this goes the next time it will rocket to massive price

seems like the price has stabilised at the 10's, and given that we are in the moment before news comes out, I'm going to start topping up.
from 2019 to 2021 there has been a fantastic growth of this companies products, patents, and partnerships.
imagine Nvida, Amazon, or Google picking these guys up to get the tech quickly, could be looking at £1 or more, massive pay day for holders :)

I wonder if we didn't have C19, would this be flying higher now as the hospitals wouldn't be busy with PPE issues and sorting out that crisis?

a lot of news due on projects, and a ton of products/patents in the pipeline, and day great news can drop with the potential of very quickly reaching the 30/40s or above regions, based on medical market potential :)

DYPR GLA

price is very stable despite a high ratio of sales today, wonder if the MM know something is happening or news in the pipeline?

Be interesting to know if the new stonechecker 2.0 software will be moving away from TexRad to reduce royalty payments, or if it's such an upgrade that it locks in the relationship with Feedback.

Either way, very excited about the new growing world and revenue of AI medical tech.

long live the new age of crypto, fiat currency are the past and controlled by corrupt bank cabals

seems like a no brainer, that if you are having a CT Scan you would ask the doctor / hospital to also run the images from IQAI checker to make sure there are 2 layers of checks.

the age of AI assist medicine is here, and can see mass adoption happening this year, bases on the stress of C19 on the medical systems and needing to process patients faster.

With the current shortage of radiologists in Europe expected to continue in the future, this profession is facing multiple challenges, the largest of which is time. At any given time in the UK, there are an estimated 330,000 X-rays which have been waiting more than 30 days for a report. In many European countries, a double reading process is necessary and in southern European countries chest X-rays and mammograms still need to be printed.

https://www.healtheuropa.eu/what-are-the-benefits-of-ai-in-radiology-and-how-can-it-be-implemented/104791/

As AI drives breakthroughs in high-performance computing, advanced tools are necessary to help organizations visualize and interact with massive data sets. Alliances like NVIDIA and AWS can take the complexity out of deploying GPU-accelerated software. Rather than spending time searching for the latest frameworks and patches, developers can now access all their resources in one place to build, train and deploy AI apps.

https://www.eweek.com/networking/nvidia-opens-ai-s torefront-in-aws-marketplace